Organovo presents FXR314 data in 3D models of Crohn's disease and ulcerative colitis

VivoSim Labs, INC.

FXR314, a clinical-stage FXR agonist, tested in human primary cell 3D models.
Data presented at Crohn's & Colitis Congress, Jan 25-27, 2024 in Las Vegas.
Presentation covers models for both Crohn's disease and ulcerative colitis.
Presentation current as of January 25, 2024; furnished as Exhibit 99.1.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.